Clinical significance of matrix metalloproteinase (MMP)-2 and MMP-9 expression in laryngeal squamous cell carcinoma

Dejan Rašić; Aleksandar Perić; Biserka Vukomanović Djurdjević; Jelena Sotirović; Nenad Baletić; Milanko Milojević; Ljubomir Pavićević; Aleksandar Dimić

doi:10.2298/vsp191223015R

Dejan Rašić Military Medical Academy, Clinic for Otorhinolaryngology, Belgrade, Serbia
Aleksandar Perić Military Medical Academy, Clinic for Otorhinolaryngology, Belgrade, Serbia
Biserka Vukomanović Djurdjević University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, Serbia
Jelena Sotirović Military Medical Academy, Clinic for Otorhinolaryngology, Belgrade, Serbia
Nenad Baletić Military Medical Academy, Clinic for Otorhinolaryngology, Belgrade, Serbia
Milanko Milojević Military Medical Academy, Clinic for Otorhinolaryngology, Belgrade, Serbia
Ljubomir Pavićević Military Medical Academy, Clinic for Otorhinolaryngology, Belgrade, Serbia
Aleksandar Dimić Military Medical Academy, Clinic for Otorhinolaryngology, Belgrade, Serbia

DOI: https://doi.org/10.2298/vsp191223015R

Keywords: biomarkers, glottis, immunohistochemistry, larynx, neoplasms, laryngitis, matrix metalloproteinases

Abstract

Background/Aim. The previous researches suggest that matrix metalloproteinases (MMPs) have the ability to degrade extracellular matrix components and play an important role in malignant tumour progression and metastasis. The aim of this study was to investigate MMP-2 and MMP-9 expression in the tissue of laryngeal squamous cell carcinoma (LSCC) and to evaluate their clinical significance. Methods. In this prospective study the samples of tumour tissue of seventy patients with LSCC (45 glottic and 25 supraglottic), and samples of laryngeal mucosa of 70 patients with chronic laryngitis were immunohistochemically stained for MMP-2 and MMP-9. We studied the relationships between MMPs tissue expression and clinical and histological characteristics of the patients with LSCC in comparison to the patients with chronic laryngitis. Results. MMP-2 and MMP-9 expression was significantly higher in the tissue of both glottic and supraglottic LSCC than in chronically inflamed laryngeal mucosa (p < 0.001 and p < 0.001, respectively). There were positive correlations between epithelial MMP-2 expression and the presence of perineural invasion (r = 0.515, p < 0.008), lymphovascular invasion (r = 0.559, p < 0.004) and disease recurrence (r = 0.415, p < 0.039) in supraglottic LSCC, as well as between MMP-2 expression and the presence of the exophytic type of tumour growth (r = 0.347, p < 0.020) in glottic LSCC. Epithelial MMP-9 expression was associated with lymphovascular invasion (r = 0.331, p < 0.026) and the presence of the exophytic tumour growth (r = 0.474, p < 0.001) in glottic LSCC. Conclusion. MMP-2 and MMP-9 can be used as potential biomarkers for the assessment of LSCC progression.

References

Smee R, Williams JR, Kotevski DP. Management of locally advanced T3-4 glottic laryngeal carcinomas. J Laryngol Otol 2018; 132(7): 642−50.

Tang D, Tao L, Zhou L, Zhang M, Wu X, Li X, et al. Retrospective analysis of 659 laryngeal squamous cell carcinoma patients treated with open laryngeal function-preserving operations. Acta Otolaryngol 2018; 138(11): 1043−50.

Whittaker M, Ayscough A. Matrix metalloproteinases and their inhibitors: current status and future challenges. Celltransmissions 2001; 17(1): 3−14.

Gou X, Chen H, Jin F, Wu W, Li Y, Long J, et al. Expressions of CD147, MMP-2 and MMP-9 in laryngeal carcinoma and its correlation with poor prognosis. Pathol Oncol Res 2014; 20(2): 475−81.

Rydlova M, Holubec L Jr, Ludvikova M Jr, Kalfert D, Franekova J, Povysil C, et al. Biological activity and clinical implications of the matrix metalloproteinases. Anticancer Res 2008; 28(2B): 1389−97.

Deschler DG, Moore MG, Smith RV. Quick Reference Guide to TNM Staging of Head and Neck Cancer and Neck Dissection Classification, 5th ed. Alexandria, VA: American Academy of Otolaryngology – Head and Neck Surgery Foundation; 2014.

Peschos D, Damala C, Stefanou D, Tsanou E, Assimakopoulos D, Vougiouklakis T, et al. Expression of matrix metalloproteinase-9 (gelatinase B) in benign, premalignant and malignant laryngeal lesions. Histol Histopathol 2006; 21(6): 603−8.

Uloza V, Liutkevicius V, Pangonyte D, Lesauskaite V. Characteristics of expression of matrix metalloproteinases (MMP-2 and MMP-9) in glottic squamous cell carcinoma and benign vocal fold lesions. Clin Exp Otorhinolaryngol 2015; 8(1): 57−64.

Lotfi A, Mohammadi G, Saniee L, Mousaviagdas M, Chavoshi H, Tavassoli A. Serum level of matrix metalloproteinase-2 and -9 in patients with laryngeal squamous cell carcinoma and clinical significance. Asian Pac J Cancer Prev 2015; 16(4): 1327−30.

Liu WW, Zeng ZY, Wu QL, Hou JH, Chen YY. Overexpression of MMP-2 in laryngeal squamous cell carcinoma: a potential indicator for poor prognosis. Otolaryngol Head Neck Surg 2005; 132(3): 395−400.

Wael S, Manal S. Expression of nm23H1 and MMP2 in laryngeal carcinoma and its role in aggressiveness of the tumour and node metastasis. Egypt J Otolaryngol 2013; 29(2): 86−92.

Akdeniz O, Akduman D, Haksever M, Ozkarakas H, Muezzinoglu B. Relationships between clinical behavior of laryngeal squamous cell carcinomas and expression of VEGF, MMP-9 and E-cadherin. Asian Pac J Cancer Prev 2013; 14(9): 5301−10.

Sarioglu S, Ozer E, Kirimca F, Sis B, Pabuccuoglu U. Matrix metalloproteinase-2 expression in laryngeal preneoplastic and neoplastic lesions. Pathol Res Pract 2001; 197(7): 483−6.

Yuce I, Bayram A, Caglı S, Canoz O, Bayram S, Guney E. The role of CD44 and matrix metalloproteinase-9 expression in predicting neck metastasis of supraglottic laryngeal carcinoma. Am J Otolaryngol 2011; 32(2): 141−6.

Mallis A, Teymoortash A, Mastronikolis NS. MMP-2 expression in 102 patients with glottic laryngeal cancer. Eur Arch Otorhinolaryngol 2012; 269(2): 639−42.

Cao XL, Xu RJ, Zheng YY. Expression of type IV collagen, metalloproteinase-2, metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in laryngeal squamous cell carcinomas. Asian Pac J Cancer Prev 2011; 12(12): 3245−9.

Wittekindt C, Jovanovic N, Guntinas-Lichius O. Expression of matrix metalloproteinase-9 (MMP-9) and blood vessel density in laryngeal squamous cell carcinomas. Acta Otolaryngol 2011; 131(1): 101−6.

Colovic Z, Pesutić-Pisac V, Poljak NK, Racić G, Cikojević D, Kontić M. Expression of matrix metalloproteinase-9 in patients with squamous cell carcinoma of the larynx. Coll Antropol 2013; 37(1): 151−5.

Kalfert D, Ludvikova M, Topolcan O, Windrickova J, Malirova E, Pesta M, et al. Analysis of preoperatice serum levels of MMP-1, -2, -9 in patients with site-specific head and neck squamous cell cancer. Anticancer Res 2014; 34(12): 7431−41.

Li JZ, Gao W, Lei WB, Zhao J, Chan JY, Wei WI, et al. MicroRNA 744-3p promotes MMP-9 mediated metastasis by simultaneously suppressing PDCD4 and PTEN in laryngeal squamous cell carcinoma. Oncotarget 2016; 7(36): 58218−23.

Popov TM, Stancheva G, Goranova TE, Rangachev J, Konov D, Todorov S, et al. Strong correlation between mRNA expression levels of HIF-2α, VEGFR1, VEGFR2 and MMP2 in laryngeal carcinoma. Pathol Oncol Res 2016; 22(4): 741−6.